Capstone Therapeutics Corp banner
Financial profile · FY2019

A pre-commercial biotech with episodic licensing receipts and recurring cash burn

The supplied history shows no recurring product-revenue base, while operating costs have generally exceeded revenue and operating cash flow. A disclosed license payment was episodic, leaving operations dependent on external funding rather than a self-funding product business.

What the latest results confirm

The 2019 results maintain the established loss-making, cash-consuming pattern after an isolated positive operating-cash-flow year; no recurring revenue base emerged. This leaves funding, rather than internally generated cash, central to sustaining development and operations.

What matters next

Whether new funding or license-related receipts replenish cash sufficiently to cover operating needs and near-term liabilities.

Balance Sheet

USD
Metric FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017 FY2018 FY2019
24.4m 13.8m 10.2m 6.3m 2.2m 1m 698k 1.3m 1.3m 58k
24.4m 13.8m 10.2m 6.3m 2.2m 1m 698k 1.3m 1.3m 58k
0 — — — — — — — — —
600k 800k 400k 200k 555k 247k 131k 98k 97k 226k
25m 14.5m 10.6m 6.5m 2.7m 1.3m 829k 1.4m 1.4m 284k
300k 200k 0 0 0 0 0 0 — 0
300k 200k 0 0 0 — — — — —
(1m) (1.2m) (700k) (300k) (255k) — — — — —
— — 1m 800k 666k 509k 353k 196k 39k 0
25.3m 14.7m 11.6m 7.3m 3.4m 1.8m 1.2m 1.6m 1.5m 284k
200k 100k 200k 100k 124k 254k 249k 197k 245k 1.2m
900k 0 100k 0 158k 7k 55k 2k 1k 5k
0 0 0 0 0 0 0 0 0 0
700k 0 — — — — — — — —
1.8m 100k 300k 100k 282k 261k 304k 199k 246k 1.2m
0 0 0 0 0 1m 1m 2.2m 2.5m 3.1m
— — 200k — 0 0 0 0 — (641k)
1.8m 100k 500k 100k 282k 1.3m 1.3m 2.4m 2.7m 3.6m
15.6m 0 0 0 20k 20k 20k 27k 27k 0
(180.4m) (174.5m) (178.1m) (182m) (186.2m) (189m) (189.6m) (191.4m) (191.8m) (193.8m)
188.3m 189.1m 189.2m 189.2m 189.3m 189.4m 189.5m 190.5m 190.5m 190.5m
— — — — — — — — — 0
23.5m 14.6m 11.1m 7.2m 3.1m 506k (122k) (879k) (1.2m) (3.3m)
25.3m 14.7m 11.6m 7.3m 3.4m 1.8m 1.2m 1.6m 1.5m 284k
1.4k 1.4k 1.4k 1.4k 1.4k 1.4k 1.4k 1.8k 1.8k 1.8k